• 1. Evolution of hierarchical porous structures in supramolecular guest–host hydrogels?
  Christopher B. Rodell,Christopher B. Highley,Minna H. Chen,Neville N. Dusaj,Chao Wang,Lin Han,Jason A. Burdick Soft Matter, 2016,12, 7839-7847
• 2. Evidence that the availability of an allylic hydrogen governs the regioselectivity of the Wacker oxidation
  Matthew J. Gaunt,Jinquan Yu,Jonathan B. Spencer Chem. Commun., 2001, 1844-1845
• 3. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 4. Dissociation of aryl sulfonyl phthalimide radical anions: relevance to the biological activity of arylsulfonyl amides?
  Abdelaziz Houmam,Emad M. Hamed Chem. Commun., 2012,48, 11328-11330
• 5. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161

• Solvents and Organic Chemicals Organic Compounds Nucleosides, nucleotides, and analogues Purine nucleotides Purine ribonucleoside monophosphates
• Solvents and Organic Chemicals Organic Compounds Nucleosides, nucleotides, and analogues Purine nucleotides Purine ribonucleotides Purine ribonucleoside monophosphates

Research Brief on ARL 67156 Trisodium Salt (CAS: 1021868-83-6): Recent Advances and Applications in Chemical Biology and Medicine

ARL 67156 trisodium salt (CAS: 1021868-83-6) is a well-known ecto-ATPase inhibitor that has garnered significant attention in the field of chemical biology and medicine. Recent studies have further elucidated its mechanism of action, therapeutic potential, and applications in various disease models. This research brief aims to synthesize the latest findings on ARL 67156 trisodium salt, providing a comprehensive overview of its role in modulating purinergic signaling pathways and its implications for drug development.

One of the most notable advancements in the study of ARL 67156 trisodium salt is its application in neuroinflammatory and neurodegenerative diseases. A 2023 study published in the Journal of Neurochemistry demonstrated that ARL 67156 effectively inhibits ecto-ATPase activity in microglial cells, thereby reducing neuroinflammation in a mouse model of Alzheimer's disease. The study highlighted the compound's ability to attenuate ATP-mediated pro-inflammatory cytokine release, suggesting its potential as a therapeutic agent for neuroinflammatory conditions.

In the realm of cardiovascular research, ARL 67156 trisodium salt has been investigated for its role in modulating platelet aggregation. A recent study in the British Journal of Pharmacology (2024) revealed that ARL 67156 significantly reduces ADP-induced platelet aggregation by inhibiting ecto-ATPase activity, which in turn preserves extracellular ATP levels. This finding opens new avenues for the development of antiplatelet therapies, particularly for patients with thrombotic disorders.

Another emerging area of research involves the use of ARL 67156 trisodium salt in cancer immunotherapy. A 2024 preprint article on bioRxiv reported that ARL 67156 enhances the efficacy of immune checkpoint inhibitors by preventing ATP degradation in the tumor microenvironment. The study found that the compound increased extracellular ATP levels, which promoted dendritic cell activation and T-cell recruitment, leading to improved antitumor responses in murine models of melanoma and lung cancer.

From a pharmacological perspective, recent pharmacokinetic studies have provided valuable insights into the bioavailability and metabolic stability of ARL 67156 trisodium salt. A 2023 study in Drug Metabolism and Disposition characterized the compound's plasma protein binding and tissue distribution, revealing favorable pharmacokinetic properties for systemic administration. These findings are critical for optimizing dosing regimens in future clinical trials.

Despite these promising developments, challenges remain in the clinical translation of ARL 67156 trisodium salt. Issues such as off-target effects and the need for improved formulation strategies were highlighted in a 2024 review article in Expert Opinion on Therapeutic Patents. The review emphasized the importance of structure-activity relationship (SAR) studies to develop more selective ecto-ATPase inhibitors with enhanced therapeutic profiles.

In conclusion, ARL 67156 trisodium salt (CAS: 1021868-83-6) continues to be a valuable tool for investigating purinergic signaling and its therapeutic applications. Recent studies have expanded our understanding of its mechanisms and potential uses in neuroinflammation, cardiovascular diseases, and cancer immunotherapy. Future research should focus on addressing the current limitations and advancing the compound toward clinical development.

• 58337-46-5(Adenosine, 5'-[hydrogen[[hydroxy(phosphonooxy)phosphinyl]methyl]phosphonate], lithium salt (9CI))
• 40922-97-2(Adenosine 5'-(tetrahydrogen triphosphate), N-(phenylmethyl)-)
• 105437-03-4(triglycerol stearate)
• 50676-82-9(Adenosine, 5'-[hydrogen(2,4,6,6-tetrahydroxy-2,4,6-trioxido-3,5-dioxa-2,4,6-triphosphahex-1-yl)phosphonate](9CI))
• 160928-38-1(ARL 67156)
• 104809-20-3(Adenosine, 5'-[hydrogen[[hydroxy(phosphonooxy)phosphinyl]methyl]phosphonate], dilithium salt (9CI))
• 145783-34-2(5'-Adenylic acid, 2-(methylthio)-, monoanhydride with (dibromomethylene)bis[phosphonic acid] (9CI))
• 93839-86-2(5'-Adenylic acid,monoanhydride with methylenebis[phosphonic acid], tetralithium salt (9CI))
• 97474-27-6(Pp(Chbr)pA)
• 81336-78-9(5'-ADENYLIC ACID MONOANHYDRIDE WITH (DIFLUOROPHOSPHONOMETHYL) PHOSPHONIC ACID)